Publications by authors named "B Kwiatkowska"
Objectives: To investigate the association between risk of different co-morbidities and diagnosis of rheumatoid arthritis (RA) using a temporal approach.
Methods: Retrospective, case-control study. Data were extracted from all healthcare claims for Poland between 2011-2021.
Article Synopsis
- Wormian bones (WB) are additional bone structures found in cranial sutures, and their presence may indicate developmental instability, particularly in males due to higher susceptibility to environmental disturbances.
- A study analyzed 317 adult skeletons from Polish and Lithuanian series and noted significant differences in WB presence between sexes, with a higher percentage of males exhibiting WB compared to females.
- Results show that the occurrence and number of WB are significantly higher in males, emphasizing the necessity for more research on sexual dimorphism in WB, particularly in populations outside of Asia.
Objectives: To evaluate the pricing of etanercept (ETN) reference and biosimilar drugs in a changing competitive to monopolized market.
Methods: We conducted a comprehensive, retrospective analysis of ETN market competition, specifically changes in tender price based on shifts in market monopoly, including the effects on cost evolution, in the off-patent market in Poland. We included a total of 473 tenders for ETN purchase in dedicated biologic drug reimbursement programs, covering both pre-filled syringes and automatic injectors.
To assess the incidence and prevalence of rheumatoid arthritis (RA) in Poland for the period 2013-2021, total and dependent on gender, age, region and serological status. Information on reported National Health Fund (NHF) health services and reimbursed prescriptions were used, defining an RA patient as a person who had at least two visits in different quarters with ICD-10 code M05 or M06 and at the same time filled at least one reimbursed prescription for a drug whose active substance is methotrexate, sulfasalazine, leflunomide or was treated with biologic disease-modifying anti-rheumatic drugs (bDMRDs) or targeted synthetic DMARDs (tsDMARDs) as part of a drug program financed by the National Health Fund. The nationwide standardised incidence rate of RA in 2021 was 29 persons per 100,000 population (18 per 100,000 population of seropositive vs.
View Article and Find Full Text PDFAs severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evolves, infection management in vulnerable populations requires formalized guidance. Although low-virulence variants of SARS-CoV-2 remain predominant, they pose an increased risk of severe illness in adults with rheumatic and musculoskeletal diseases (RMDs). Several disease-specific (chronic long-grade inflammation, concomitant immunosuppression) and individual (advanced age, multimorbidity, pregnancy, vaccination status) factors contribute to excess risk in RMD populations.
View Article and Find Full Text PDF